Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Active Biotech AB Presents Follow-Up Data from Prostate Cancer Project with Tasquinimod Performed in Collaboration with EXINI Diagnostics AB (publ)

Monday, 3 Jun 2013 09:00am EDT 

Active Biotech AB announced that the Company has presented Phase II retrospective follow-up data from the prostate cancer project with tasquinimod at the scientific conference 2013 ASCO Annual Meeting held in Chicago (the United States). This study was performed in collaboration with EXINI Diagnostics AB (publ). The results show that Bone Scan Index (BSI) can be a more objective radiologic assessment in trials of men with metastatic castration-resistant prostate cancer, and is clearly associated with prognosis and disease burden. Tasquinimod had a favorable impact on the BSI over time, confirming the Company's original findings in the randomized phase 2 trial. The ability to obtain objective measures of bone metastases can help fuel drug development in this disease, where current bone scan assessments are often misclassified and very subjective. 

Company Quote

0.2 +1.20%
7:54am EST